Research Use Only

Retatrutide

40 mg Vial

Triple Agonist (GLP-1/GIP/Glucagon) Research Peptide

VIAL
40 mg
FORM
Lyophilized Powder

Product Information

Active
Retatrutide — 40 mg
Form
Lyophilized powder for reconstitution
Common Reconstitution
2 mL (200 units) = 20 mg/mL (5 units = 1 mg)

Hormone & Metabolic Considerations

Retatrutide is a next-generation triple agonist (GLP-1/GIP/glucagon) that builds upon the mechanisms of Ozempic (semaglutide, GLP-1) and Tirzepatide (GLP-1/GIP). It can influence appetite, blood sugar, weight, and energy expenditure. As with any research compound that affects metabolism, regular bloodwork and monitoring is recommended before, during, and after use.

It activates GLP-1, GIP, and glucagon receptors. Individual responses (including glucose control and GI effects) vary widely. Monitoring with lab work helps track effects. CGM devices are generally indicated for people with diabetes.

Research Use Information

Intended Research Target

This product is intended for research on metabolic health, weight management, and glucose control in contexts such as obesity or diabetes models.

Important Factors
Make sure to consume recommended protein daily to help preserve lean mass during research involving weight loss compounds like Retatrutide.

Example: For a person with 150 lbs of lean body mass, a common target is roughly 0.8–1 g of protein per lb of lean mass, which equals approximately 120–150 grams of protein per day. Adjust based on individual research goals and bloodwork.
Common Titration Schedule (Example from Research Contexts)
Week Dose
10.75 mg
21.5 mg
32.25 mg
43.0 mg
53.75 mg
6+Up to 6.0 mg (maintenance — adjust based on response)

Note: Reconstitute with bacteriostatic water (2 mL / 200 units = 20 mg/mL, where 5 units = 1 mg). Always follow sterile technique. Since Retatrutide takes time to become fully effective, you might not experience the full effects until targeting 4–6 mg weekly.

Frequently Asked Questions

How does Retatrutide work?

Retatrutide is a next-generation triple agonist (GLP-1/GIP/glucagon) that builds upon the mechanisms of Ozempic (semaglutide) and Tirzepatide. It can reduce appetite, improve blood sugar control, and increase energy expenditure in research settings.

What side effects are commonly discussed?

GI effects (nausea, reduced appetite, constipation) are the most frequently reported. Heart rate increases and other metabolic changes can also occur. Slower titration helps with tolerance.

What is the half-life?

Approximately 5–6 days, which supports once-weekly dosing in research settings.

What is the amino acid chain length?

Retatrutide is a 39-amino acid peptide.

Storage & Handling

Store lyophilized powder in refrigerator or cool, dark place.

After reconstitution with bacteriostatic water, refrigerate.

Use sterile technique for reconstitution and injections.

LEGAL & RESEARCH DISCLAIMER

This product is sold strictly for research and laboratory use only. It is not intended for human consumption, medical treatment, or any therapeutic purpose. The information on this page is for educational and research reference purposes only.

Retatrutide is investigational. Any use outside controlled research is at the sole risk of the individual. Always comply with all applicable laws.

Stacked Biologics • Research Chemical Division • All Rights Reserved. This page accompanies the labeled research chemical product. Scan the QR code on the bottle to return to this information.

EXPLORE OUR RESEARCH LINEUP
Enclomiphene 25 mg/mL BPC-157 Oral 500 mcg GHK-Cu 2% Facial Serum

Each product has its own dedicated research information page. All products sold for research use only.